Literature DB >> 29023976

Peripheral nerve involvement in multiple sclerosis: Demonstration by magnetic resonance neurography.

Johann M E Jende1, Gesa H Hauck1,2, Ricarda Diem3, Markus Weiler3, Sabine Heiland1,4, Brigitte Wildemann3, Mirjam Korporal-Kuhnke3, Wolfgang Wick3, John M Hayes5, Johannes Pfaff1, Mirko Pham1,6, Martin Bendszus1, Jennifer Kollmer1.   

Abstract

OBJECTIVE: To detect and quantify peripheral nerve lesions in multiple sclerosis (MS) by magnetic resonance neurography (MRN).
METHODS: Thirty-six patients diagnosed with MS based on the 2010 McDonald criteria (34 with the relapsing-remitting form, 2 with clinically isolated syndrome) with and without disease-modifying treatment were compared to 35 healthy age-/sex-matched volunteers. All patients underwent detailed neurological and electrophysiological examinations. Three Tesla MRN with large anatomical coverage of both legs and the lumbosacral plexus was performed by using 2-dimensional (2D) fat-saturated, T2-weighted (T2w) and dual echo turbo spin echo sequences as well as a 3D T2-weighted, fat-saturated SPACE sequence. Besides qualitative visual nerve assessment, a T2w signal quantification was performed by calculation of proton spin density and T2 relaxation time. Nerve diameter was measured as a morphometric criterion.
RESULTS: T2w hyperintense nerve lesions were detectable in all MS patients, with a mean lesion number at thigh level of 151.5 ± 5.7 versus 19.1 ± 2.4 in controls (p < 0.0001). Nerve proton spin density was higher in MS (tibial/peroneal: 371.8 ± 7.7/368.9 ± 8.2) versus controls (tibial/peroneal: 266.0 ± 11.0/276.8 ± 9.7, p < 0.0001). In contrast, T2 relaxation time was significantly higher in controls (tibial/peroneal: 82.0 ± 2.1/78.3 ± 1.7) versus MS (tibial/peroneal: 64.3 ± 1.0/61.2 ± 0.9, p < 0.0001). Proximal tibial and peroneal nerve caliber was higher in MS (tibial: 52.4 ± 2.1mm2 , peroneal: 25.4 ± 1.3mm2 ) versus controls (tibial: 45.2 ± 1.4mm2 , p < 0.0015; peroneal: 21.3 ± 0.7mm2 , p = 0.0049).
INTERPRETATION: Peripheral nerve lesions could be visualized and quantified in MS in vivo by high-resolution MRN. Lesions are defined by an increase of proton spin density and a decrease of T2 relaxation time, indicating changes in the microstructural organization of the extracellular matrix in peripheral nerve tissue in MS. By showing involvement of the peripheral nervous system in MS, this proof-of-concept study may offer new insights into the pathophysiology and treatment of MS. Ann Neurol 2017;82:676-685.
© 2017 American Neurological Association.

Entities:  

Mesh:

Year:  2017        PMID: 29023976     DOI: 10.1002/ana.25068

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  16 in total

Review 1.  Peripheral nervous system in multiple sclerosis-understanding the involvement via autonomic nervous system.

Authors:  Ivan Adamec; Magdalena Krbot Skorić; Mario Habek
Journal:  Neurol Sci       Date:  2021-05-25       Impact factor: 3.307

2.  Relapsing paralytic ileus in multiple sclerosis requiring surgery: a video case report.

Authors:  G Chiaro; C Fratila; F Martig; C Zecca; C Gobbi
Journal:  Clin Auton Res       Date:  2018-11-10       Impact factor: 4.435

3.  Dorsal Root Ganglion Volumetry by MR Gangliography.

Authors:  S Weiner; M Strinitz; J Herfurth; F Hessenauer; C Nauroth-Kreß; T Kampf; G A Homola; N Üçeyler; C Sommer; M Pham; M Schindehütte
Journal:  AJNR Am J Neuroradiol       Date:  2022-04-21       Impact factor: 3.825

4.  Quantification and Proximal-to-Distal Distribution Pattern of Tibial Nerve Lesions in Relapsing-Remitting Multiple Sclerosis : Assessment by MR Neurography.

Authors:  Adriana M Pietsch; Andrea Viehöver; Ricarda Diem; Markus Weiler; Mirjam Korporal-Kuhnke; Brigitte Wildemann; Georges Sam; John M Hayes; Olivia Fösleitner; Johann M E Jende; Sabine Heiland; Martin Bendszus; Jennifer C Hayes
Journal:  Clin Neuroradiol       Date:  2022-10-20       Impact factor: 3.156

5.  Autonomic symptom burden is an independent contributor to multiple sclerosis related fatigue.

Authors:  Magdalena Krbot Skorić; Luka Crnošija; Ivan Adamec; Barbara Barun; Tereza Gabelić; Tomislav Smoljo; Ivan Stanić; Tin Pavičić; Ivan Pavlović; Jelena Drulović; Tatjana Pekmezović; Mario Habek
Journal:  Clin Auton Res       Date:  2018-09-12       Impact factor: 4.435

Review 6.  Inflammation and Oxidative Stress in Multiple Sclerosis: Consequences for Therapy Development.

Authors:  Valentina Pegoretti; Kathryn A Swanson; John R Bethea; Lesley Probert; Ulrich L M Eisel; Roman Fischer
Journal:  Oxid Med Cell Longev       Date:  2020-05-12       Impact factor: 6.543

7.  Association of Serum Cholesterol Levels With Peripheral Nerve Damage in Patients With Type 2 Diabetes.

Authors:  Johann M E Jende; Jan B Groener; Christian Rother; Zoltan Kender; Artur Hahn; Tim Hilgenfeld; Alexander Juerchott; Fabian Preisner; Sabine Heiland; Stefan Kopf; Mirko Pham; Peter Nawroth; Martin Bendszus; Felix T Kurz
Journal:  JAMA Netw Open       Date:  2019-05-03

8.  Patients with chronic autoimmune demyelinating polyneuropathies exhibit cognitive deficits which might be associated with CSF evidence of blood-brain barrier disturbance.

Authors:  Yavor Yalachkov; Valerie Uhlmann; Johannes Bergmann; Dilara Soydaş; Stefan Frisch; Marion Behrens; Christian Foerch; Johannes Gehrig
Journal:  PLoS One       Date:  2020-02-04       Impact factor: 3.240

9.  Length-dependent MRI of hereditary neuropathy with liability to pressure palsies.

Authors:  Michael Pridmore; Ryan Castoro; Megan Simmons McCollum; Hakmook Kang; Jun Li; Richard Dortch
Journal:  Ann Clin Transl Neurol       Date:  2019-12-24       Impact factor: 4.511

10.  Magnetization transfer ratio quantifies polyneuropathy in hereditary transthyretin amyloidosis.

Authors:  Jennifer Kollmer; Ute Hegenbart; Christoph Kimmich; Ernst Hund; Jan C Purrucker; John M Hayes; Stephen I Lentz; Georges Sam; Johann M E Jende; Stefan O Schönland; Martin Bendszus; Sabine Heiland; Markus Weiler
Journal:  Ann Clin Transl Neurol       Date:  2020-04-25       Impact factor: 4.511

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.